PURPOSE: This study was designed to assess exhaled hydrogen peroxide (H(2)O(2)), blood serum antioxidant capacity, and tumor necrosis factor-alpha (TNFalpha) in primary breast cancer (PBC). METHODS: The study included 34 consecutive, non-smoking PBC patients (aged 62.5 +/- 13.5 at surgery) prior to the treatments, qualified for modified radical mastectomy and not undergoing any adjuvant systemic therapy, and 33 healthy controls. The post surgery pathological assessment included tissue expression of estrogen (ER) and progesterone (PR) receptors, and epidermal growth factor receptor type 2 (HER-2/neu). Exhaled H(2)O(2) was determined fluorometrically in the exhaled breath condensate (EBC). Blood serum antioxidant capacity and TNFalpha levels were assessed with ferric reducing ability of plasma (FRAP) and ELISA immunoassay, respectively. RESULTS: In PBC patients, 10 ER, 11 PR, and 9 HER-2/neu positive tumors were identified and HER-2/neu score was 2+ in 20% of all tumors. Median (Me) H(2)O(2) was increased up to 0.44 microM (interquartile range IR: 0.20-1.25 microM) compared with healthy control of 0.36 microM (IR: 0.12-0.48 microM; p < 0.05). The H(2)O(2) concentration in EBC was significantly correlated (tau = 0.27; p = 0.03) and increased in cases with nodal metastases (n = 12; p = 0.04). Serum TNFalpha was increased up to 51.7 +/- 21.0 pg/ml compared with controls 17.2 +/- 3.65 pg/ml (p < 0.05). FRAP was increased to 1.41 +/- 0.37 mM Fe(2+) compared with control 1.19 +/- 0.17 mM Fe(2+); (p = 0.006). CONCLUSIONS: This is the first study to demonstrate increased H(2)O(2) in exhaled breath condensate in patients with localized breast malignancy and its relation with clinical severity.
PURPOSE: This study was designed to assess exhaled hydrogen peroxide (H(2)O(2)), blood serum antioxidant capacity, and tumor necrosis factor-alpha (TNFalpha) in primary breast cancer (PBC). METHODS: The study included 34 consecutive, non-smoking PBCpatients (aged 62.5 +/- 13.5 at surgery) prior to the treatments, qualified for modified radical mastectomy and not undergoing any adjuvant systemic therapy, and 33 healthy controls. The post surgery pathological assessment included tissue expression of estrogen (ER) and progesterone (PR) receptors, and epidermal growth factor receptor type 2 (HER-2/neu). Exhaled H(2)O(2) was determined fluorometrically in the exhaled breath condensate (EBC). Blood serum antioxidant capacity and TNFalpha levels were assessed with ferric reducing ability of plasma (FRAP) and ELISA immunoassay, respectively. RESULTS: In PBCpatients, 10 ER, 11 PR, and 9 HER-2/neu positive tumors were identified and HER-2/neu score was 2+ in 20% of all tumors. Median (Me) H(2)O(2) was increased up to 0.44 microM (interquartile range IR: 0.20-1.25 microM) compared with healthy control of 0.36 microM (IR: 0.12-0.48 microM; p < 0.05). The H(2)O(2) concentration in EBC was significantly correlated (tau = 0.27; p = 0.03) and increased in cases with nodal metastases (n = 12; p = 0.04). Serum TNFalpha was increased up to 51.7 +/- 21.0 pg/ml compared with controls 17.2 +/- 3.65 pg/ml (p < 0.05). FRAP was increased to 1.41 +/- 0.37 mM Fe(2+) compared with control 1.19 +/- 0.17 mM Fe(2+); (p = 0.006). CONCLUSIONS: This is the first study to demonstrate increased H(2)O(2) in exhaled breath condensate in patients with localized breast malignancy and its relation with clinical severity.
Authors: Michael Phillips; Renee N Cataneo; Beth Ann Ditkoff; Peter Fisher; Joel Greenberg; Ratnasiri Gunawardena; C Stephan Kwon; Olaf Tietje; Cynthia Wong Journal: Breast Cancer Res Treat Date: 2006-02-24 Impact factor: 4.872
Authors: Wim B M Gerritsen; Jerryll Asin; Pieter Zanen; Jules M M van den Bosch; Fred J L M Haas Journal: Respir Med Date: 2005-01 Impact factor: 3.415
Authors: J Rysz; R A Stolarek; A Pedzik; J Fijalkowska; M Luczynska; A Sarniak; M Kasielski; A Makowka; M Nowicki; D Nowak Journal: Int J Artif Organs Date: 2007-10 Impact factor: 1.595
Authors: Elena M V de Cavanagh; Alba E Honegger; Erica Hofer; Raul H Bordenave; Eduardo O Bullorsky; Norma A Chasseing; Cesar Fraga Journal: Cancer Date: 2002-06-15 Impact factor: 6.860
Authors: Michael P Lisanti; Ubaldo E Martinez-Outschoorn; Zhao Lin; Stephanos Pavlides; Diana Whitaker-Menezes; Richard G Pestell; Anthony Howell; Federica Sotgia Journal: Cell Cycle Date: 2011-08-01 Impact factor: 4.534
Authors: Michael Phillips; J David Beatty; Renee N Cataneo; Jan Huston; Peter D Kaplan; Roy I Lalisang; Philippe Lambin; Marc B I Lobbes; Mayur Mundada; Nadine Pappas; Urvish Patel Journal: PLoS One Date: 2014-03-05 Impact factor: 3.240